Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
LOKELMA vs SODIUM ZIRCONIUM CYCLOSILICATE
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Patiromer, a non-absorbed potassium-binding polymer, exchanges calcium for potassium ions in the gastrointestinal tract, thereby increasing fecal potassium excretion and lowering serum potassium levels.
Sodium zirconium cyclosilicate is a non-absorbed, inorganic, potassium-selective cation exchanger that binds potassium ions in the gastrointestinal tract, thereby reducing the absorption of potassium and facilitating its fecal excretion. It exchanges sodium and hydrogen for potassium in the gut lumen.
Treatment of hyperkalemia,Off-label: Management of hyperkalemia in patients with chronic kidney disease on renin-angiotensin-aldosterone system inhibitors
FDA-approved: Treatment of hyperkalemia in adults.,Off-label: Chronic hyperkalemia management in patients on renin-angiotensin-aldosterone system inhibitors; acute hyperkalemia in emergency settings (limited data).
5 g (one packet) orally three times daily; titrate to maintain serum potassium 4.0-5.0 m Eq/L; maximum 15 g three times daily (45 g/day).
5 g orally three times daily.
Not applicable as LOKELMA is not systemically absorbed; terminal half-life is not measurable in traditional sense. Clinical effect duration correlates with gastrointestinal transit time (~6-8 hours for peak potassium lowering).
Not applicable as the drug acts locally in the GI tract without systemic absorption; clinical effect persists for duration of dosing.
Patiromer is not absorbed systemically and not metabolized; it is excreted unchanged in feces.
Sodium zirconium cyclosilicate is not systemically absorbed and is eliminated unchanged in feces. No hepatic metabolism or cytochrome P450 involvement.
Primarily eliminated unchanged in feces (approximately 90%) via gastrointestinal transit; <1% excreted in urine as absorbed sodium zirconium cyclosilicate is negligible.
Primarily eliminated unchanged in feces (>99%); negligible renal excretion (<1%) as the drug is not absorbed systemically.
Not bound to plasma proteins as it is non-absorbed and acts locally in the gastrointestinal tract.
Not applicable; <0.1% absorbed systemically, so protein binding is negligible.
Not applicable (locally acting, non-absorbed); apparent Vd is negligible due to lack of systemic absorption.
Not applicable; negligible systemic distribution due to lack of absorption (Vd not measurable).
Oral bioavailability is <1% as the drug is not absorbed from the gastrointestinal tract.
Oral: <0.1% due to minimal absorption; acts locally in gastrointestinal tract.
No dose adjustment required based on GFR; monitor serum potassium more frequently in patients with e GFR <30 m L/min/1.73m² due to increased risk of hypokalemia.
No dose adjustment required for any degree of renal impairment.
No dose adjustment required for Child-Pugh Class A, B, or C; use with caution in severe hepatic impairment due to limited data.
No dose adjustment required for any degree of hepatic impairment.
Safety and efficacy not established in pediatric patients; no approved dosing recommendations.
Safety and efficacy not established in pediatric patients.
No specific dose adjustment; monitor serum potassium and renal function due to age-related decline in renal function and increased risk of hypokalemia.
No specific dose adjustment recommended; use with caution due to potential for electrolyte disturbances.
None
None
WARNING: Risk of hypomagnesemia; monitor serum magnesium. WARNING: Potential for gastrointestinal obstruction or perforation; use with caution in patients with severe gastrointestinal disorders. WARNING: May bind to other oral medications; separate dosing by at least 3 hours (or 6 hours for certain drugs).
Edema: Contains sodium; caution in patients with heart failure or requiring sodium restriction (each 5 g dose provides ~400 mg sodium).,Gastrointestinal effects: Constipation, fecal impaction (especially in elderly or those with decreased GI motility).,Hypokalemia: Monitor serum potassium regularly; may cause hypokalemia if not titrated appropriately.,Drug interactions: Separate dosing from oral medications (take at least 2 hours apart) due to potential adsorption.,Severe constipation: Discontinue if bowel obstruction suspected.
Absolute: Hypersensitivity to patiromer or any excipient. Relative: Severe constipation, bowel obstruction, or impaction; postoperative gastrointestinal surgery.
Absolute: Hypersensitivity to sodium zirconium cyclosilicate or any component.,Relative: Severe constipation, bowel obstruction, or impaired GI motility (e.g., postoperative ileus) – use only if benefits outweigh risks.,Relative: Concomitant use with agents that cause constipation or reduce GI motility.
LOKELMA should be taken with food to reduce gastrointestinal side effects. No specific food restrictions, but high-potassium foods should be avoided as per dietary guidelines for hyperkalemia.
No specific food restrictions. However, patients should continue to follow dietary potassium restrictions as advised by their healthcare provider. SZC works in the gastrointestinal tract and does not interfere with food absorption. Avoid taking with high-fat meals as it may delay the onset of action.
No human studies. Animal reproduction studies not conducted. Insufficient data in pregnant women. Risk cannot be excluded. Due to mechanism (potassium binder, non-absorbed polymer), systemic absorption is minimal; fetal exposure unlikely. However, no controlled data. Use only if clearly needed and potential benefit justifies potential risk to fetus.
Limited human data; animal studies show no teratogenic effects at clinically relevant exposures. Not associated with structural abnormalities in first trimester. Theoretical risk of electrolyte disturbances affecting fetal development if maternal electrolyte imbalance occurs. No known risk in second or third trimester.
No data on presence in human milk, effects on breastfed infant, or on milk production. Given negligible oral absorption, excretion into breast milk is expected to be minimal. Caution advised; consider developmental and health benefits of breastfeeding alongside mother's clinical need.
No data on excretion in human milk. Sodium zirconium cyclosilicate is non-systemic and minimally absorbed (<1% oral dose), unlikely to enter breast milk. M/P ratio not calculated due to negligible systemic absorption.
No pharmacokinetic studies in pregnancy. No dose adjustment recommended based on current data. Use lowest effective dose to normalize potassium levels. Monitor potassium closely as pregnancy may alter electrolyte balance.
No dose adjustment required based on pharmacokinetic changes in pregnancy; sodium zirconium cyclosilicate acts locally in gastrointestinal tract and is not absorbed. Standard dosing: 5 g or 10 g three times daily for hyperkalemia, not to exceed 15 g per day.
LOKELMA (patiromer) is a non-absorbed potassium-binding polymer indicated for hyperkalemia. Administer at least 6 hours apart from other oral medications due to potential binding. Monitor serum potassium weekly until stable. May cause hypomagnesemia; check magnesium levels periodically. Use with caution in patients with gastrointestinal motility disorders.
Sodium zirconium cyclosilicate (SZC) is a non-absorbed potassium binder for chronic hyperkalemia. Onset of action is 1 hour; typically used for maintenance after acute correction. Do not use as emergency treatment for life-threatening hyperkalemia (prefer IV calcium, insulin+glucose). Administer at least 2 hours apart from other oral medications due to potential binding. Monitor serum potassium regularly; adjust dose based on potassium levels. Avoid in patients with severe constipation, bowel obstruction, or impaction.
Take LOKELMA exactly as prescribed, usually once daily with food.,Separate LOKELMA from other oral medications by at least 6 hours.,Do not crush, chew, or open capsules; swallow whole.,Notify your doctor if you experience constipation, nausea, or stomach pain.,Do not stop taking LOKELMA without consulting your doctor.
Take this medication exactly as prescribed, usually three times a day with meals for the first 24-72 hours, then once daily.,Do not crush or chew the powder; mix the packet with about 3 tablespoons (45 m L) of water and drink immediately.,Separate this medication from other oral medicines by at least 2 hours to avoid affecting their absorption.,You may experience constipation or swelling (edema); report severe constipation or swelling to your healthcare provider.,Do not use as a rescue treatment for sudden high potassium; seek emergency care if you have chest pain, irregular heartbeat, or muscle weakness.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about LOKELMA vs SODIUM ZIRCONIUM CYCLOSILICATE, answered by our medical review team.
LOKELMA is a Potassium Binder that works by Patiromer, a non-absorbed potassium-binding polymer, exchanges calcium for potassium ions in the gastrointestinal tract, thereby increasing fecal potassium excretion and lowering serum potassium levels.. SODIUM ZIRCONIUM CYCLOSILICATE is a Potassium Binder that works by Sodium zirconium cyclosilicate is a non-absorbed, inorganic, potassium-selective cation exchanger that binds potassium ions in the gastrointestinal tract, thereby reducing the absorption of potassium and facilitating its fecal excretion. It exchanges sodium and hydrogen for potassium in the gut lumen.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between LOKELMA and SODIUM ZIRCONIUM CYCLOSILICATE depend on the specific clinical indication. These are both Potassium Binder agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of LOKELMA is: 5 g (one packet) orally three times daily; titrate to maintain serum potassium 4.0-5.0 m Eq/L; maximum 15 g three times daily (45 g/day).. The standard adult dose of SODIUM ZIRCONIUM CYCLOSILICATE is: 5 g orally three times daily.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between LOKELMA and SODIUM ZIRCONIUM CYCLOSILICATE in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. LOKELMA is classified as Category C. No human studies. Animal reproduction studies not conducted. Insufficient data in pregnant women. Risk cannot be excluded. Due to mechanism (potassium binder, non-absorbed polymer). SODIUM ZIRCONIUM CYCLOSILICATE is classified as Category C. Limited human data; animal studies show no teratogenic effects at clinically relevant exposures. Not associated with structural abnormalities in first trimester. Theoretical risk o. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.